ecancer

ecancer.org

ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.

 

ecancer
Avatar

2020 ASCO Update on Lung Cancer: 1L Atezo + Chemo, Ongoing Survival Benefit With Durvalumab in ES-SCLC, Nivolumab in Previously Treated mNSCLC

By ecancer FEATURING Luis Raez
By ecancer FEATURING Luis Raez
430 views
September 29, 2020
2 Comments
Login to view comments. Click here to Login

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

20:09
AstraZeneca Oncology

Management Strategies for Anemia in First-line Maintenance Therapy f…

Feat. D. Czel, C. Arn
Lung Cancers
05:04
ecancer

AACR 2024 Insights: "FLAURA2 Exploratory Analysis of Baseline a…

Feat. P. Janne
08:38
ecancer

Anti-Tumor Activity of Tusamitamab Ravtansine Combined With Pembro +…

Feat. L. Paz-Ares
14:27
ecancer

Latest in Lung Cancer Genomic Testing

Feat. S. Popat
21:41
ecancer

EGFR Testing in NSCLC: Best Practice for Patients With Exon 20 Inser…

Feat. A. Passaro, U. Malapelle, J. Sabari
05:22
ecancer

ESMO 2021 Updates on 1L Nivo+Ipi for Unresectable Malignant Pleural …

Feat. S. Peters
27:51
ecancer

ESMO 2021: Surveying Latest Updates in EGFRm Advanced NSCLC

Feat. A. Minchom, N. Leighl, V. Moreno, C. Cabrera
06:09
ecancer

ESMO 2021 Highlights on Atezo vs. BSC After Adjuvant Chemo for Stage…

Feat. E. Felip
09:54
ecancer

ESMO 2021 Updates on Amivantamab +/- Lazertinib in Post-Osimertinib …

Feat. P. Tomasino, C. Shu
04:06
ecancer

1L Nivo+Ipi+Chemo for Patients With Advanced NSCLC and Brain Mets: R…

Feat. D. Carbone
15:19
ecancer

WCLC Highlights on NSCLC: Is Sotorasib Effective in KRAS G12C-Mutate…

Feat. L. Raez
07:53
ecancer

ESMO 2020 Update on Stage 4 NSCLC: CPIs + Chemo, PD-L1, EGFR, and Ot…

Feat. L. Raez
28:45
ecancer

ESMO 2020 Expert Discussion on EGFR Exon 20 Insertions in NSCLC: Wha…

Feat. A. Spira, B. Besse, A. Passaro, M. Thomas
06:03
ecancer

2020 ESMO Update on ALK+ NSCLC: Lorlatinib vs. Crizotinib Efficacy D…

Feat. S. Peters, F. Cappuzzo, A. Passaro, S. Popat
06:22
ecancer

ESMO 2020 Update on Adjuvant Osimertinib for Resected EGFRm NSCLC: I…

Feat. S. Peters, F. Cappuzzo, A. Passaro, S. Popat
03:54
ecancer

ESMO 2020 LungART Update on Completely Resected NSCLC: Is DFS Better…

Feat. S. Peters, F. Cappuzzo, A. Passaro, S. Popat
03:09
ecancer

ESMO 2020 IMpower133 Update on ES-SCLC: Is 1L Chemo+/-Atezo Benefici…

Feat. S. Peters, F. Cappuzzo, A. Passaro, S. Popat
07:47
ecancer

ESMO 2020 Updates on NSCLC: 1L Cemiplimab vs. Platinum-Doublet Chemo…

Feat. S. Peters, F. Cappuzzo, A. Passaro, S. Popat
04:56
ecancer

ESMO 2020 Update on LS-SCLC: Ipi and Nivo vs. Observation After CRT

Feat. S. Peters, F. Cappuzzo, A. Passaro, S. Popat
07:22
ecancer

2020 ESMO Updates on Advanced NSCLC: Adjuvant Osimertinib for EGFRm …

Feat. B. Gyawali
10:34
ecancer

Pathologist's Perspective on KRAS Inhibitors in NSCLC: What Is …

Feat. R. Büttner
12:00
ecancer

2020 ESMO LungART Update on Radiation Therapy in Completely Resected…

Feat. C. Le Péchoux
16:22
ecancer

2020 ESMO Update on Advanced EGFR-Mutated NSCLC: How Effective Is EG…

Feat. A. Spira, J. Sabari
05:51
ecancer

2020 ESMO Update on Advanced ALK+ NSCLC: Brigatinib vs. Crizotinib -…

Feat. S. Popat
06:30
ecancer

2020 ESMO ADAURA CNS Analysis: What's Next for Adjuvant Osimert…

Feat. M. Tsuboi
09:45
ecancer

2020 ASCO Update on LS-SCLC: Is High-Dose Twice-Daily Thoracic RT Le…

Feat. B. Henning Grønberg
07:22
ecancer

2020 ASCO Update on Adjuvant Osimertinib in EGFR+ NSCLC: Are the Res…

Feat. L. Raez
06:40
ecancer

2020 ASCO Update on Lung Cancer: 1L Atezo + Chemo, Ongoing Survival …

Feat. L. Raez
06:03
ecancer

2020 ASCO Update on Stage 4/Recurrent NSCLC: Should We Treat Patient…

Feat. M. Reck
05:03
ecancer

The Role of Adjuvant Therapy in EGFRm Resectable NSCLC: Overview of …

Feat. R. Herbst
15:35
ecancer

Expert Discussion on EGFRm NSCLC: What Are the Latest Developments?

Feat. A. Spira